Metabolic Health

5-Amino-1MQ A synthetic small molecule studied as an inhibitor of NNMT, an enzyme implicated in obesity and metabolic dysregulation, with additional research in aged muscle regeneration. View research notes → AOD-9604 AOD-9604 is a synthetic fragment of human growth hormone studied for its lipolytic and antilipogenic properties. Unlike intact hGH, it does not bind the GH receptor, which means researchers can examine its fat-metabolism effects in isolation. View research notes → Cagrilintide Cagrilintide is a long-acting amylin analog that has been studied extensively in combination with semaglutide. Here is what the Phase 3 data looks like. View research notes → CJC-1295 CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH), engineered to bind albumin and extend its half-life from minutes to roughly a week. Here is what the human and animal research actually shows. View research notes → CJC-1295 (with DAC) + Ipamorelin Two peptides that target different points in the growth hormone axis are frequently studied in combination. This page covers what the research actually shows for each. View research notes → CJC-1295 No DAC + Ipamorelin CJC-1295 No DAC and Ipamorelin are studied in combination because they activate two different receptor systems in the growth hormone axis, producing additive GH pulses through independent pathways. This page covers what the research shows. View research notes → GHRP-2 GHRP-2 is a synthetic hexapeptide that acts as a potent ghrelin receptor agonist, stimulating growth hormone release from the pituitary. Researchers study it for GH axis activation, diagnostic testing, and the physiological effects of ghrelin pathway stimulation. View research notes → GHRP-6 The original growth hormone releasing peptide, developed in 1984. Researchers studying the GH axis often compare GHRP-6 with its successors as a reference compound. View research notes → Glutathione Glutathione is the body's primary intracellular antioxidant — a tripeptide it manufactures itself. Levels decline with age and chronic disease, and research has examined whether supplementation can reverse that decline. View research notes → IGF-1 LR3 IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1, engineered to resist the binding proteins that limit native IGF-1's half-life. The research is entirely preclinical: animal models and cell culture. Here is an honest look at what that literature says. View research notes → Ipamorelin Ipamorelin is a selective growth hormone secretagogue studied for its ability to stimulate GH release without significant effects on cortisol or prolactin. Here is a look at the current research. View research notes → Melanotan II Melanotan II is a synthetic alpha-MSH analog studied for skin pigmentation, sexual function, and melanocortin receptor pharmacology. It is the precursor compound that led to the development of PT-141 (bremelanotide), which is FDA-approved for women's sexual dysfunction. View research notes → MOTS-c A peptide encoded within mitochondrial DNA, studied as a regulator of metabolic homeostasis and an exercise mimetic with potential relevance to aging and insulin sensitivity. View research notes → NAD+ One of the most-studied molecules in longevity science. NAD+ is a coenzyme rather than a peptide, but is widely tracked alongside research peptides for its role in aging, cellular repair, and metabolic function. View research notes → Retatrutide Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly, simultaneously activating the GIP, GLP-1, and glucagon receptors. Phase 2 trials showed approximately 24% mean body weight reduction at 48 weeks, the largest reported for any obesity drug to date. View research notes → Semaglutide Semaglutide has more large-scale human trial data behind it than almost any other peptide women research, and most of what's written about it still ignores the questions women actually ask: what it does to weight at midlife, what the PCOS research shows, and what a fair per-mg price looks like. Here is the evidence, the FDA picture, and the pricing, plainly. View research notes → Sermorelin Sermorelin is a synthetic fragment of growth hormone-releasing hormone studied for its ability to stimulate endogenous GH secretion. Researchers have examined its use in growth hormone deficiency, body composition, and age-related hormonal decline. View research notes → Tesamorelin Tesamorelin is a synthetic GHRH analog FDA-approved as Egrifta for excess visceral fat in people with HIV. Researchers also study it for liver fat reduction, metabolic health, and potential cognitive effects in populations with growth hormone dysregulation. View research notes → Tirzepatide Tirzepatide targets two incretin receptors at once, and in the trial record that has meant the largest weight reductions yet measured in a drug study, results that matter to the women comparing it against semaglutide for midlife metabolic research. Here is what the evidence actually shows, including the heart failure finding that is especially relevant to women. View research notes →